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AbstrACt
Introduction Walking exercise is a recommended 
but underused treatment for intermittent claudication 
caused by peripheral arterial disease (PAD). 
Addressing the factors that influence walking 
exercise may increase patient uptake of and 
adherence to recommended walking. The primary 
aim of this randomised controlled trial (RCT) is 
to evaluate the efficacy of a physiotherapist-led 
behavioural change intervention on walking ability 
in adults with intermittent claudication (MOtivating 
Structured walking Activity in people with Intermittent 
Claudication (MOSAIC)) in comparison with usual care.
Methods and analysis The MOSAIC trial is a two-
arm, parallel-group, single-blind RCT. 192 adults will 
be recruited from six National Health Service Hospital 
Trusts. Inclusion criteria are: aged ≥50 years, PAD 
(Ankle Brachial Pressure Index ≤0.90, radiographic 
evidence or clinician report) and intermittent 
claudication (San Diego Claudication Questionnaire), 
being able and willing to participate and provide 
informed consent. The primary outcome is walking 
ability (6 min walking distance) at 3 months. Outcomes 
will be obtained at baseline, 3 and 6 months by an 
assessor blind to group allocation. Participants will 
be individually randomised (n=96/group, stratified 
by centre) to receive either MOSAIC or usual care 
by an independent randomisation service. Estimates 
of treatment effects will use an intention-to-treat 
framework implemented using multiple regression 
adjusted for baseline values and centre.
Ethics and dissemination This trial has full ethical 
approval (London—Bloomsbury Research Ethics 
Committee (17/LO/0568)). It will be disseminated via 
patient forums, peer-reviewed publications and conference 
presentations.
trial registration number ISRCTN14501418
IntroduCtIon
background and objectives
Walking exercise is an effective treatment 
for intermittent claudication,1 an ischaemic 
leg pain caused by peripheral arterial disease 
(PAD). It improves walking distances and 
duration compared with usual National 
Health Service (NHS) treatment2 or phar-
maceutical therapy3 and has comparable 
long-term outcomes to revascularisation.4 5 
The Trans-Atlantic Inter-Society Consensus-II 
group recommend supervised walking exer-
cise at an intensity that induces pain within 
3–5 min, for 30–60 min/session conducted 
three times/week for 3 months.6 Similarly, the 
National Institute for Health and Care Excel-
lence recommends 2 hours of supervised exer-
cise/week for 3 months.7 However, guideline 
implementation is poor8–10 and, even when 
strengths and limitations of this study
 ► This is the first trial to investigate the efficacy of a 
physiotherapist-led behavioural change interven-
tion on walking ability in people with intermittent 
claudication.
 ► This trial collects validated objective and self-report-
ed outcomes of walking ability.
 ► Clinician’s experiences of training and delivering 
MOtivating Structured walking Activity in people 
with Intermittent Claudication and intervention fi-
delity will be explored to inform implementation into 
practice.
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supervised exercise therapy is available, patient uptake 
and adherence is variable.11 Consequently, the usual 
care for most individuals with intermittent claudication 
is simple walking advice, however, despite advice, self-di-
rected walking is frequently overlooked as a management 
strategy,12 participation is low10 13 and often ineffective.14
Adopting and maintaining a new health behaviour, such 
as walking exercise, is challenging and people with inter-
mittent claudication frequently do not achieve walking 
recommendations.11 15 16 Barriers to walking exercise in 
people with intermittent claudication include the need to 
stop and rest to alleviate pain, the impact of undulating 
terrain and a lack of clarity around the recommendations 
for walking.13 17 These challenges can be difficult to over-
come without appropriate guidance and support.
Structured home‐based exercise programmes may 
offer a promising alternative to supervised exercise 
therapy.18 19 These programmes typically include exercise 
sessions completed away from a healthcare facility with 
support from healthcare professionals and may overcome 
the barriers of accessibility and availability.14 18 20 Evidence 
from recent systematic reviews suggests that structured 
home exercise may improve walking performance 
although the quality of the included trials is mixed and 
few studies evaluate systematically developed interven-
tions which incorporate theoretically informed strate-
gies to facilitate the uptake and long-term adherence to 
walking exercise.14 20
Crucial conditions to support health behavioural 
change, such as increasing self-directed walking exer-
cise, are an individual’s capability (eg, knowledge and 
understanding that walking exercise is a treatment for 
intermittent claudication), opportunity (eg, identifying 
an appropriate environment place to walk) and motiva-
tion (eg, attitudes and beliefs about walking as a treat-
ment).21–23 Evidence suggests that targeting these factors 
using behavioural change techniques (eg, setting walking 
goals, action planning22 24 or motivational interviewing25) 
in addition to exercise or advice may increase walking 
ability in people with intermittent claudication.24 26
Motivating Structured walking Activity in people with 
Intermittent Claudication (MOSAIC) is a structured, phys-
iotherapist-led behavioural change intervention, which 
aims to increase walking in people with intermittent clau-
dication. It is informed by two psychological models (1) 
the theory of planned behaviour27 28 and (2) the common-
sense model of illness representations.29 30 The theory of 
planned behaviour proposes that people use informa-
tion (eg, social, personal and environmental conditions) 
around them to make decisions about whether to perform 
a behaviour (eg, walking exercise).27 28 Interventions 
underpinned by the theory of planned behaviour have 
shown utility in physical activity behavioural change,31 
and the sociocognitive factors defined by this model are 
associated with motivation to walk and walking ability in 
adults with intermittent claudication.23 32 The common-
sense model of illness representations proposes that indi-
viduals form personal, lay explanations of their illness 
(eg, PAD) and symptoms (eg, intermittent claudication), 
which guides how they manage their condition and seek 
treatment.29 30 The common-sense model has been instru-
mental in understanding how people cope with long-term 
illness.33 Illness perceptions defined by the common-sense 
model, including beliefs about PAD, its causes and one’s 
ability to control or manage the condition and symptoms, 
are associated with walking ability in people with intermit-
tent claudication.23
MOSAIC was systematically developed to target the 
salient factors identified from these two models12 23 and 
includes behavioural change techniques to facilitate 
the uptake and maintenance of walking exercise.24 This 
protocol was informed by a preliminary study which 
demonstrated that the MOSAIC intervention and trial 
procedures were acceptable to participants and clinicians 
and feasible to deliver.26
objectives
The primary objective is to answer the question: Does 
MOSAIC improve walking ability (measured by the 6 min 
walking distance, 6MWD) at the primary endpoint of 
3 months compared with usual care in older adults with 
intermittent claudication?
The secondary objectives include answering the 
questions:
1. Does MOSAIC improve (a) activities of daily living and 
quality of life (QoL) at 3 months and (b) walking abil-
ity, activities of daily living and QoL at 6 months com-
pared with usual care in older adults with intermittent 
claudication?
2. Is it feasible to collect resource use data using a mod-
ified measure in older adults with intermittent claudi-
cation?
3. What are the minimal clinically important difference 
(MCID) values for the clinical assessments used for 
older adults with intermittent claudication?
MEthods
trial design
A phase II, prospective, assessor blinded, multicentre, 
parallel group, two-arm, randomised, controlled superi-
ority trial with nested qualitative study (figure 1).
Participant eligibility criteria
Individuals will be eligible for the trial if they meet the 
following inclusion criteria: (1) adults ≥50 years of age; 
(2) established PAD (determined by either Ankle Brachial 
Pressure Index ≤0.90, radiographic evidence or clinician 
report) and intermittent claudication (reported on the 
San Diego Claudication Questionnaire34); (3) able and 
willing to participate in MOSAIC and provide informed 
consent.
Individuals may not enter the study if they meet the 
following exclusion criteria: (1) unstable intermittent 
claudication (eg, self-reported change in symptoms 
during previous 3 months in response to the question 
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Figure 1 Trial flow chart.
(2) walking >90 min/week (reported on the Brief Inter-
national Physical Activity Questionnaire (IPAQ)35); 
(3) contraindications to walking exercise (eg, unstable 
angina) confirmed by the direct care team; (4) have 
completed any prescribed supervised exercise sessions in 
the previous 6 months or been offered prescribed super-
vised exercise sessions in the next 6 months.
setting
Participants will be recruited from five NHS Foundation 
Trusts in London (Guy’s and St Thomas’, King’s College, 
St George’s, Royal Free, Royal London) and one in the 
South East of England (Ashford and St Peter’s), UK. The 
MOSAIC intervention is delivered either at the partici-
pants’ home or a private room in the participating site to 
allow flexibility, inclusivity and confidentiality, while mini-
mising contamination.
Interventions
Motivating structured walking Activity in people with 
Intermittent Claudication
Participants randomised to the intervention group will 
receive the MOSAIC intervention in addition to the usual 
care provided by their direct care team.
MOSAIC aims to increase an individual’s walking ability. 
It comprises two 60 min face-to-face consultations (weeks 
1 and 2) and two 20 min follow-up telephone calls (weeks 
6 and 12). The content of each session is standardised 
and incorporates 15 behavioural change techniques, but 
sessions may be tailored based on participants’ knowl-
edge, goals, symptoms and current walking (tables 1 and 
2). Walking plans will be agreed collaboratively between 
the participant and the physiotherapist and include 
progressive, individualised targets for walking frequency, 
intensity and duration to achieve recommendations 
(30–50 min of walking three times/week at an intensity 
that elicits pain within 3–5 min).6 MOSAIC is supple-
mented by an interactive participant manual, containing 
worksheets and a walking diary, and by a pedometer.
Physiotherapist training and supervision
The MOSAIC sessions will be delivered by experienced 
physiotherapists (band 6 and above) who will be trained 
in motivational interviewing and behavioural change 
techniques. All trial physiotherapists will receive 2 days 
training on the trial objectives, research processes, 
underpinning psychological theories and MOSAIC inter-
vention content, delivery and materials. Trial physiother-
apists will be explicitly instructed on how to identify and 
report any adverse events and about the risks and conse-
quences of contamination. Training will be delivered by 
the trial team (LB, JW, MGH, JB, GF and BV) and an 
accredited provider of motivational interviewing training 
(Pip Mason Consultancy). A bespoke manual will support 
training and delivery of MOSAIC and includes an inter-
vention checklist for each session.
To promote consistency of intervention delivery, all 
face-to-face and telephone sessions will be audiorecorded 
and individualised feedback on at least one of the first 
face-to-face and telephone MOSAIC sessions will be 
provided to each physiotherapist by a member of the 
trial team (LB and BV). Physiotherapists will record each 
session on a checklist (eg, duration, content), which will 
be reviewed by members of the trial team for adherence 
to the intervention. The trial physiotherapists will attend 
regular meetings supervised by members of the trial team 
(JW, LB and BV) to maintain skills and receive feedback 
and support.
usual care
Participants randomised to the comparison group will 
continue to receive usual care provided by the NHS for 
intermittent claudication. Usual care is typically delivered 
in the vascular outpatient clinic by a vascular surgeon 
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information about PAD and lifestyle modifications (eg, 
smoking cessation, diet and weight management), super-
vised exercise, risk factor management including lipid 
modification, statin therapy and antiplatelet therapy, 
pharmacotherapy to improve leg function (vasodilators 
such as naftidrofuryl oxalate) or revascularisation (eg, 
angioplasty, stenting and bypass).7 Participants may seek 
concomitant treatment during the trial if they wish to. 
Any other treatments accessed by participants, (eg, from 
their general practitioner/other health professionals), 
will be recorded on a modified Client Service Receipt 
Inventory36 at follow-up.
Participant identification and recruitment
Potentially eligible patients will be identified by one of 
two methods which will proceed in parallel:
1. Patients will be approached by the direct care team 
during routine clinical appointments at participating 
sites. Potential participants will be provided with an 
explanation of the trial, an invitation letter and par-
ticipant information sheet and, if interested, asked to 
provide permission to be contacted by the study re-
cruitment personnel.
2. Patients will be identified from existing clinical lists/
databases (depending on availability of these at partici-
pating sites) and will be sent an invitation pack includ-
ing: an invitation letter, participant information sheet, 
consent to be contacted form and prepaid return en-
velope. Non-responders will be contacted by telephone 
approximately 4 weeks later.
Patients expressing an interest in participating in the 
trial will be contacted by the study recruitment personnel 
to complete full eligibility screening. Eligible patients 
who do not wish to take part in the trial will be asked if 
their age and gender may be recorded and if they wish to 
provide a reason for opting not to participate.
Eligible patients will be invited to attend an appoint-
ment at their participating site to provide written 
informed consent and complete a baseline assessment.
randomisation, blinding and allocation concealment
Outcome measures will be collected by an independent 
assessor who will attend each site and will be masked to 
group allocation. The independent assessor will not be 
involved in delivering MOSAIC.
Following baseline data collection, the independent 
assessor will notify a web-based randomisation service to 
randomise each participant. The randomisation service 
is provided by the UK Clinical Research Collaboration 
Registered King’s Clinical Trials Unit and will ensure 
prospective registration and allocation concealment. 
Randomisation will be at the level of the individual, using 
block randomisation with randomly varying block sizes, 
stratified by centre. The online randomisation system will 
generate emails automatically to delegated members of 
the research team and the allocating trial physiothera-
pists at the study sites. The allocating trial physiothera-
pists will coordinate the delivery of MOSAIC at the study 
site but will not share this information with the indepen-
dent assessor.
The recruiting personnel and independent assessor 
are masked to group allocation. The trial statistician, 
the research staff undertaking the qualitative study, the 
participants and the trial physiotherapists are not masked 
to group allocation.
outcome assessment
Measures will be conducted immediately before randomi-
sation (baseline), and at 3 months and 6 months post-ran-
domisation (table 3).
data collection
Written informed consent will be obtained prior to any 
data collection. Baseline and 3-month follow-up measures 
will be conducted face to face by an independent assessor 
who will attend each site. At 6 months, the outcomes will 
be collected either electronically or via a standard postal 
questionnaire pack (with prepaid return envelope).
Data will be collected and stored using a secure data-
base system. Participants opting to complete self-re-
ported assessments electronically will be provided with a 
unique username and password to log onto the database 
and complete measures either during the face-to-face 
appointment (baseline and 3 months) or from home (at 
6 months). Any research data completed by pencil and 
paper will be entered to the secure database by the inde-
pendent outcome assessor or trial research assistant.
At 3-month follow-up, participants who are unable or 
refuse to attend an appointment to complete the primary 
outcome will be invited to complete the secondary 
outcomes at home either electronically or by post.
Attrition will be minimised via standardised text, email 
and telephone reminders. Following these, if no data have 
been returned, the assessor will telephone the participant 
to collect a minimum data set (table 3).
baseline measures
At baseline, participants will complete a bespoke socio-
demographic and clinical characteristics questionnaire 
(including age, sex, smoking history, comorbidities and 
claudication symptom classification (San Diego Claudica-
tion Questionnaire34). Standard measures of body mass 
index and Ankle-Brachial Pressure Index37 will also be 
determined in addition to the outcomes detailed below.
Primary outcome
The primary outcome is the difference in mean 6MWD in 
metres at 3 months between groups. This will be assessed 
by a self-paced 6 min walk test over a 60.96 m (200 foot) 
circuit.38–40 Pain intensity will be measured before and 
after the walk test using a standardised pain scale for clau-
dication.41 The walk test will be completed twice, with the 
highest 6MWD used for analysis.
secondary outcome measures
Other measures will be used to assess the broader effects 
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Maximal walking ability (duration walked before 
resting (seconds)) and pain-free walking ability (dura-
tion walked before reported pain onset (seconds)) 
will be recorded during the 6 min walk test.42 43 These 
parameters evaluate the global and integrated physiolog-
ical responses of all systems involved with exercise and 
symptom manifestation.
Self-reported maximal walking distance (SR-MWD) will 
be measured by one global item: ‘What is the maximum 
distance (in metres) you can walk at your usual pace on 
a flat surface before leg pain forces you to stop?’44 and 
the 4-item Walking Estimated-Limitation Calculated by 
History questionnaire (WELCH).45 46
Nottingham Extended Activities of Daily Living scale 
(NEADL)47 48 is a 22-item measure with 4 subscales (mobility, 
kitchen tasks, domestic tasks and leisure activities) and will 
assess function.
The 6-item disease specific Vascular Quality of Life Ques-
tionnaire-6 (VascuQol-6)49 and the EQ-5D-5L will assess 
QoL.50
The 7-item Brief IPAQ will estimate daily physical activity.35
Adverse events will be recorded by asking participants a 
single open-ended item: ‘Have you had any problems since 
your last assessment?’ at 3 and 6-month follow-up. Trial 
physiotherapists will also report any adverse events in partic-
ipants randomised to receive the MOSAIC intervention.
To determine the MCID, participants will provide a 
global rating of change score after five measures (6MWD, 
SR-MWD, WELCH, NEADL and VascuQoL-6) at the 3 and 
6-month follow-up assessments. In response to the ques-
tion: ‘Has there been any change in your walking ability/
walking distance/daily activities etc since the last test?’ 
participants will be asked to rate their perceived change on 
a transitional three-point scale (1, worse; 2, about the same; 
3, better). If they indicate no change, the participant will 
score 0. If they indicate there has been an improvement or 
deterioration, they will be asked to score their change on a 
15-point Likert scale: (−7=a very great deal worse to 7=a very 
great deal better). Scores of −1, 0 and 1 will be considered 
no change, scores of 2–3 small improvement and scores of 
4–7 substantial improvement.51 52
Process variables
Process variables will be collected to investigate the imple-
mentation and maintenance, unexpected pathways and 
consequences, and mechanisms of impact of MOSAIC.
Attendance at MOSAIC sessions will be recorded by 
the trial physiotherapists. Adherence to walking goals 
will be assessed by the 6-item Exercise Adherence Rating 
Scale53 54 at 3 and 6-month follow-up.
Fidelity to the MOSAIC intervention will be assessed in 
a random subset of ≥10% of the audio-recorded MOSAIC 
sessions/physiotherapist by two independent raters using 
bespoke, standardised checklists.
The type and duration of usual care and non-NHS care 
received by both groups will be recorded using the modi-
fied Client Service Receipt Inventory36 to evaluate unex-
pected pathways and consequences.
Proposed mechanisms of impact include changes to 
theoretically defined sociocognitive variables targeted 
by MOSAIC. The Brief Illness Perception Questionnaire 
(a 9-item measure of individuals’ representation of their 
illness as defined by the common-sense model),55 the 
Theory of Planned Behaviour Questionnaire (a 12-item 
measure of goals and beliefs about walking as treatment 
for intermittent claudication)32 and the action planning 
and action control scale (a self-regulation question-
naire)56 57 will be assessed at each time point.
resource use variables
The study is an important opportunity to assess the feasi-
bility of collecting data on resource use in adults with inter-
mittent claudication to inform future trials. A modified 
Client Service Receipt Inventory36 will be used to record 
information on service utilisation, income, accommoda-
tion and other cost-related variables at all time points to 
determine completion rates and redundant questions.
Qualitative study
To explore the experience of MOSAIC treatment and 
participation in the trial, semistructured, audio-recorded 
interviews will be conducted with up to 30 participants 
or until data saturation of themes is reached. A purpo-
sive sampling strategy will ensure that a range of partic-
ipants are selected (eg, age, symptoms, group allocation 
and recruitment site). Interviews will be conducted via 
telephone or face to face (depending on participant pref-
erence) after completion of the final assessment. A subsa-
mple of physiotherapists will be interviewed to explore 
their experiences of training and delivering MOSAIC by 
an independent researcher, supported by experienced 
qualitative researchers in the trial team.12 13 58 59 Interview 
schedules will be developed iteratively, and the questions 
asked may develop as insights from ongoing interviews 
and analyses reveal additional areas of relevance. Inter-
views will be transcribed verbatim, anonymised and anal-
ysed thematically by one researcher.60 The initial codes 
will be cross-referenced with a second researcher and 
the development of themes will be discussed with the 
trial team to provide different perspectives on coding. 
Themes will be presented to a sample of interviewees to 
ensure resonance and plausibility of the themes.
PAtIEnt And PublIC InvolvEMEnt
User involvement is central to the design and manage-
ment of the MOSAIC trial. Patients were involved in the 
identification of the research question and two patient 
advisers reviewed the protocol and assisted in the devel-
opment of all patient-related materials. One patient 
adviser is a funding coapplicant. Our patient advisers will 
be members of the trial management group, contribute 
to the trial physiotherapist training and dissemination. 
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dAtA And stAtIstICAl AnAlysIs PlAn
sample size
Based on previous work,61 192 participants will be 
required to detect a mean 6MWD difference of 58 m 
(SD=111; α=0.05, 1-β=0.90), accounting for 20% attrition 
at 3-month follow-up.
statistical analysis
A statistical analysis plan will be written by the trial statis-
tician (SE) and agreed with the trial management group 
and joint trial steering committee/data monitoring and 
ethics committee. Analyses of primary and secondary 
outcomes and process variables will be conducted on an 
intention-to-treat basis and all included participants will 
be analysed as randomised.
The primary outcome will be analysed using multiple 
regression and adjusted for baseline 6MWD and site. 
Results will be reported as the difference in mean 6MWD 
between the intervention and control groups with 95% 
CIs. Other continuous outcomes and process variables 
will be similarly analysed. If appropriate, a mediation 
analysis using linear regression will examine mechanisms 
of impact.
Descriptive statistics for sociodemographic and clinical 
characteristics, attendance at MOSAIC sessions, adher-
ence to treatment and referral to or uptake of other 
treatments will be computed. Adverse events and serious 
adverse events will be described.
To determine the MCID, change scores for the five 
clinical measures will be calculated by subtracting the 
baseline result from the follow-up results for each partic-
ipant. Correlations will be computed for participant 
self-assessment of performance scores and change in 
clinical outcomes. The mean change in scores for partic-
ipants reporting no change, small improvement and 
substantial improvement will be compared by analysis 
of variance. The sensitivity and specificity for change in 
score to distinguish participants classified as changed 
(≥2) from those whose performance was unchanged (−1 
to +1) will be calculated and a receiver operating charac-
teristic curve obtained.62 The data point corresponding 
to the upper left corner of the curve will represent the 
MCID.
As a sensitivity analysis, the MCID will be also calculated 
using a distribution-based approach. The SE of measure-
ment for all participants scores will be used to estimate 





where  σ1  is the baseline SD and r represents the intra-
class correlation coefficient, which is a measure of the 
test–retest reliability of the scale. The intraclass correla-
tion coefficient will be calculated using the baseline and 
follow-up scores for each participant. Using this method, 
1 SE of measurement represents the estimated MCID.63
If the proportion of missing data is above 10%, multiple 
imputation will be considered as a sensitivity analysis for 
the primary outcome, and for the secondary outcomes 
used in the 3 and 6-month MCID.64
dAtA MAnAgEMEnt And MonItorIng
Data will be collected and retained in accordance with the 
Data Protection Act 1998, the General Data Protection 
Regulation 2016/679, and the Data Protection Policy of 
King's College London. Data for each participant will be 
identified by a unique identification number and entered 
onto a Food and Drug Administration compliant data-
base system. Data will be stored separately from personal 
data to maintain confidentiality. The chief investigator 
will be the custodian of the data and the data will only be 
used by the trial team.
The trial management group will be responsible for 
the management of the MOSAIC trial and will be led by 
the chief investigator. It will comprise trial investigators, 
a patient advisor and a vascular surgeon who will meet 
regularly to discuss trial progress.
A trial steering committee/data monitoring and ethics 
committee will provide study oversight. It will be inde-
pendently chaired and will include patient and public 
involvement representatives, independent, experienced 
physiotherapists, a psychologist and a statistician along 
with the chief investigator. It will be independent of both 
the trial team and sponsors and operate under an agreed 
charter (MOSAIC Trial Steering Committee/Data Moni-
toring and Ethics Committee Charter V.1.0 25 July 17).
EthICAl ConsIdErAtIons And dIssEMInAtIon
Approvals were provided from the Research and Devel-
opment departments at all participating sites. The chief 
investigator will submit and, if required, obtain approval 
from relevant parties for all substantial amendments to 
the original approved documents.
The trial will be completed in accordance with the 
Declaration of Helsinki, the International Conference 
for Harmonisation of Good Clinical Practice guidelines 
and the Research Governance Framework for Health and 
Social Care.
King’s College London and Guy’s and St Thomas’ NHS 
Foundation Trust ( R& D@ gstt. nhs. uk) are the trial spon-
sors and the lead site (Guy’s and St Thomas’ NHS Foun-
dation Trust) will monitor and audit this project to ensure 
compliance with the necessary legislation.
This is a low risk trial because MOSAIC is a non-invasive 
treatment which will be delivered by trained, registered 
physiotherapists. Any adverse events will be recorded by 
the trained, trial physiotherapists and reported to the 
trial team. Participants will also be offered the opportu-
nity to report any adverse events at follow-up assessments. 
Any serious adverse events will be referred to the chief 
investigator immediately.
dissemination
While the trial is in progress, we will disseminate trial 
updates via a dedicated website. (https://www. kcl. ac. uk/ 
lsm/ research/ divisions/ hscr/ research/ groups/ Rehabil-
itation/ MOSAIC- Trial. aspx) and social media (http:// 
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will be disseminated via patient forums, conferences 
presentations and peer-reviewed publications.
ConClusIons
The MOSAIC trial investigates the efficacy of a physio-
therapist-led, theoretically informed, behavioural change 
intervention on walking ability compared with usual care 
in older adults with intermittent claudication. It includes 
objective and self-reported measures of walking ability 
but only follows participants for 6 months. The MOSAIC 
intervention addresses a gap in the recommended care 
pathway for management of intermittent claudication, 
where walking exercise is a first-line treatment. Future 
studies should investigate the effectiveness and cost effec-
tiveness of MOSAIC.
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